Berlin: The World Health Organization says it is ending a trial into whether anti-malaria drug hydroxychloroquine helps patients hospitalised with COVID-19.

WHO said Saturday it has accepted the recommendation from the committee overseeing the trial to discontinue testing of hydroxychloroquine and lopinavir/ritonavir, a drug combination used to treat HIV/AIDS. The drugs were being compared with standard care for hospitalized patients.

WHO says a review of the interim results showed hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.

The agency adds that while there was no solid evidence of increased mortality for hospitalized patients given the drugs, there were some associated safety signals in the clinical laboratory findings of an associated trial.

WHO says the decision won't affect possible trials on patients who aren't hospitalized, or on those receiving the drugs before potential exposure to the coronavirus or shortly afterward.

Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.



Dubai/Abu Dhabi: Residents and visitors across the United Arab Emirates received a fresh emergency alert on their mobile phones stating that the situation in the country is currently safe.

The message, issued by the Ministry of Interior (MOI), thanked people for their cooperation and reassured them that conditions were stable.

“Thank you for your cooperation. We reassure you that the situation is currently safe. You may resume your normal activities while continuing to remain cautious and take the necessary precautions, and to follow official instructions. (MOI),” the alert read.

The notification was sent in both Arabic and English through the country’s emergency alert system.

The advisory comes after earlier alerts warning of potential missile threats amid rising regional tensions. Authorities have urged the public to stay cautious and follow official guidance.